Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547019 | 1.00 | LMNA (0.56) | LMNAHPGDCYP1A2GAAHTR6 | |
| SCHEMBL3632803 | 0.84 | LMNA (0.53) | LMNAHPGDCYP1A2GAAHTR6 | |
| Hydrochloric Acid SCHEMBL21724904 | 0.84 | SIRT1 (0.45) | LMNAHPGDCYP1A2GAAHTR6 | |
| SCHEMBL8288846 | 0.83 | TP53 (0.56) | LMNAHPGDCYP1A2GAAHTR6 | |
| SCHEMBL21980641 | 0.82 | LMNA (0.55) | LMNAHPGDCYP1A2GAAHTR6 | |
| SCHEMBL1757618 | 0.80 | LMNA (0.53) | LMNAHPGDCYP1A2GAAHTR6 | |
| SCHEMBL13997300 | 0.80 | SIRT1 (0.54) | LMNAHPGDCYP1A2GAAHTR6 | |
| SCHEMBL13174592 | 0.78 | ALDH1A1 (0.56) | LMNAHPGDGAAALDH1A1KDM4E | |
| SCHEMBL30547023 | 0.78 | ALDH1A1 (0.56) | LMNAHPGDGAAALDH1A1KDM4E | |
| SCHEMBL16688229 | 0.78 | KDM4E (0.57) | LMNAHPGDALDH1A1KDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| CN-118344279-B | Synthesis method of indole C2 benzyl C-H bond direct amine methylation | 山东第二医科大学 | 2024-08-30 | — | — | CN | disclosed |
| CN-118344279-A | Synthesis method of indole C2 benzyl C-H bond direct amine methylation | 山东第二医科大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-116730814-A | Novel naphthoquinone intermediate, preparation method thereof, chiral naphthalene compound and preparation method thereof | 香港科技大学深圳研究院 | 2023-09-12 | — | — | CN | disclosed |
| CN-110878099-B | Preparation method of pyrrole [1,2, alpha ] indole alkaloid derivative | 五邑大学 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| CN-112654354-A | 1,3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indole derivative compound and application thereof | 菲尼克思药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-110437126-B | Organocatalytic indole non-activated sp3Method and application for asymmetric functionalization of carbon-hydrogen bond | 香港科技大学深圳研究院 | 2020-11-13 | — | — | CN | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| CN-110437126-A | Organic catalysis indoles disactivation sp3The method and application of C-H bond asymmetry function dough | HKUST SHENZHEN RES INSTITUTE | 2019-11-12 | — | — | CN | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| WO-2010102393-A1 | 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS | LORUS THERAPEUTICS INC. (CA) | 2010-09-16 | — | — | WO | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| EP-0425345-A1 | Keratinic fibres dyeing process with amino-indoles, composition and use devices | L'OREAL (FR) | 1991-05-02 | — | — | EP | disclosed |
| US-4069337-A | 2-SUBSTITUTED-INDOLE-1-LOWER-ALKANECARBOXAMIDES HAVING ANTI-SECRETORY OR ANTI-ULCER ACTIVITY | STERLING DRUG INC. (US) | 1978-01-17 | — | — | US | disclosed |
| US-4021448-A | ANTISECRETORY AND ANTIULCER ACTIVITIES | STERLING DRUG INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | LMNA 2789/4885HPGD 3554/4885CYP1A2 233/4885 |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 | LMNA 1737/4885HPGD 2568/4885CYP1A2 578/4885 |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | LMNA 1875/4885HPGD 1132/4885CYP1A2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.